I am flying-off to Illinios today to cover the American Society of Clinical Oncology (ASCO) meetings in Chicago.  Here is a summary of some of the exciting cancer therapy related news we can expect to learn about there this weekend:

Update ASCO 2012: most promising new cancer drugs all targeted therapies

May 29th, 2012 by Ellen Shnidman – Imperfect Parent.com

The imminent opening of ASCO 2012 promises to be a showcase of the fruits of biotechnology research in developing targeted therapies of different classes.  These therapies attack the progression of metastatic cancer in a host of different ways. Thanks to Luke Timmerman at www.xconomy.com, we have a list of the most interesting targeted therapies to be presented at ASCO in a few days.

1. Genentech’s TDM-1 is a monoclonal antibody attached to chemotherapy providing both specificity and power to treat HER2+ breast cancer in women who are metastatic

2. Aveo’s tivozanib is a tyrosine kinase inhibitor (TKI), providing another option for advanced kidney cancer

3. Onyx’s regorafenib is a TKI to treat colorectal cancer and gastrointestinal stromal tumors

4. Onyx’s proteasome inhibitor carfilzomib will add another option for patients with multiple myeloma who have advanced beyond first or second line therapy

5. Seattle Genetics’ Adcetris is a monoclonal antibody directed against the CD30 biomarker in lymphoma patients

6. J&J’s Zytiga is going for a second indication as an enzyme blocker in the synthesis of androgen in castrate resistant prostate cancer

7. Exelisis’ cabozantinib, another TKI, is for medullary thyroid cancer

8. Medivation’s enzalytimide is an androgen receptor blocker for castrate resistant prostate cancer

9. Ariad’s ponatinib is a TKI for chronic myleoid leukemia.

Combination therapies are where it’s at–especially when treating blood cancers.  Note how many blood and bone marrow cancer therapy breakthroughs made the list…

I see multiple myeloma, lymphoma and leukemia represented.  The reason is simple.  It is difficult to target solid tumors with chemotherapy.  Oncologists and hematologists have a much better chance using chemo to fight blood cancers, where the enemy is spread throughout a patient’s system.

Makes sense, right?

I will be blogging here and on my MultipleMyelomaBlog.com several times daily starting Friday, so stay tuned. See you in Chicago!

Feel good and keep smiling!  Pat

 

Leave a Reply